Epidermal Growth Factor Receptor Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Epidermal Growth Factor Receptor stocks.

Epidermal Growth Factor Receptor Stocks Recent News

Date Stock Title
Jun 2 BMY Emerging and Chinese pharmas playing greater role in oncology drug development
Jun 1 BMY Bristol Myers lung cancer drug Krazati succeeds in late-stage trial
Jun 1 BMY KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer
May 31 MBIO Mustang Bio files for $40M mixed shelf offering
May 31 AZTR Azitra, Inc. Announces Presentation at the 2024 BIO International Convention
May 31 BMY Bristol Myers Squibb’s Breyanzi gains FDA approval for lymphoma
May 30 BMY Bristol-Myers Squibb's Options: A Look at What the Big Money is Thinking
May 30 BMY Bristol Myers' Breyanzi gains additional indication for mantle cell lymphoma
May 30 BMY Bristol Myers (BMY) Gets EC Nod for Opdivo Label Expansion
May 30 ZNTL Zentalis Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
May 29 AMGN Amgen wins approval of first biosimilar of AstraZeneca's Soliris
May 29 AMGN Amgen Secures FDA Nod For Rare-Disease Treatment Biosimilar Based On AstraZeneca's Drug
May 29 BMY Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate
May 29 BMY Bristol-Myers gets EU approval for Opdivo for bladder cancer
May 29 BMY BMS secures another EC approval for Opdivo combination
May 29 BMY BMS stakes $80m on Prothena’s neurodegenerative candidate
May 29 AMGN Where Will Amgen Be in 3 Years?
May 29 BDTX Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
May 29 ZNTL Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of Directors
May 29 BMY Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
Epidermal Growth Factor Receptor

The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is a transmembrane protein that is a receptor for members of the epidermal growth factor family (EGF family) of extracellular protein ligands.The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). In many cancer types, mutations affecting EGFR expression or activity could result in cancer.Epidermal growth factor and its receptor was discovered by Stanley Cohen of Vanderbilt University. Cohen shared the 1986 Nobel Prize in Medicine with Rita Levi-Montalcini for their discovery of growth factors.
Deficient signaling of the EGFR and other receptor tyrosine kinases in humans is associated with diseases such as Alzheimer's, while over-expression is associated with the development of a wide variety of tumors. Interruption of EGFR signalling, either by blocking EGFR binding sites on the extracellular domain of the receptor or by inhibiting intracellular tyrosine kinase activity, can prevent the growth of EGFR-expressing tumours and improve the patient's condition.

Browse All Tags